Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria.
Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria.
复制标题
DOI：
10.1016/j.drugalcdep.2013.09.026
复制
发表时间：
2014-01-01
影响因子：
4.2
通讯作者：
van den Brink W
中科院分区：
文献类型：
--
作者：
van de Glind G;Konstenius M;Koeter MWJ;van Emmerik-van Oortmerssen K;Carpentier PJ;Kaye S;Degenhardt L;Skutle A;Franck J;Bu ET;Moggi F;Dom G;Verspreet S;Demetrovics Z;Kapitány-Fövény M;Fatséas M;Auriacombe M;Schillinger A;Møller M;Johnson B;Faraone SV;Ramos-Quiroga JA;Casas M;Allsop S;Carruthers S;Schoevers RA;Wallhed S;Barta C;Alleman P;IASP Research Group;Levin FR;van den Brink W
现有研究对物质使用障碍 (SUD) 患者注意力缺陷/多动障碍 (ADHD) 患病率的估计各不相同，从 2% 到 83% 不等。需要更好地了解这种变化的可能原因以及从 DSM-IV 到 DSM-5 的变化的影响。这是一项在 10 个国家进行的两阶段国际多中心横断面研究，研究对象为酒精和/或吸毒障碍患者的住院和门诊成瘾治疗中心的患者。共有 3558 名寻求 SUD 治疗的患者接受了成人 ADHD 筛查。 1276 名受试者的子样本（包括筛查阳性和筛查阴性患者）参加了结构化诊断访谈。 DSM-IV 和 DSM-5 成人 ADHD 的患病率在 DSM-IV 中从匈牙利的 5.4%（CI 95%：2.4–8.3）到挪威的 31.3%（CI 95%：25.2–37.5），在 DSM-5 中从匈牙利的 7.6%（CI 95%：4.1–11.1）到 32.6%（CI 95%：25.2-37.5）。 26.4–38.8）（挪威）。在所有国家和中心使用相同的评估程序，可以大幅减少先前研究中报告的 SUD 患者中成人 ADHD 患病率的变异性 (2–83%→ 5.4–31.3%)。其余的差异部分是由主要滥用物质和国家（北欧与非北欧国家）造成的。 DSM-5 的患病率估计略高于 DSM-IV。鉴于成人 ADHD 的普遍较高患病率，所有寻求 SUD 治疗的患者均应进行筛查，并在确诊后接受 ADHD 治疗，因为文献表明寻求治疗的 ADHD SUD 患者的 SUD 预后较差。
Available studies vary in their estimated prevalence of attention deficit/hyperactivity disorder (ADHD) in substance use disorder (SUD) patients, ranging from 2 to 83%. A better understanding of the possible reasons for this variability and the effect of the change from DSM-IV to DSM-5 is needed. A two stage international multi-center, cross-sectional study in 10 countries, among patients form inpatient and outpatient addiction treatment centers for alcohol and/or drug use disorder patients. A total of 3558 treatment seeking SUD patients were screened for adult ADHD. A subsample of 1276 subjects, both screen positive and screen negative patients, participated in a structured diagnostic interview. Prevalence of DSM-IV and DSM-5 adult ADHD varied for DSM-IV from 5.4% (CI 95%: 2.4–8.3) for Hungary to 31.3% (CI 95%:25.2–37.5) for Norway and for DSM-5 from 7.6% (CI 95%: 4.1–11.1) for Hungary to 32.6% (CI 95%: 26.4–38.8) for Norway. Using the same assessment procedures in all countries and centers resulted in substantial reduction of the variability in the prevalence of adult ADHD reported in previous studies among SUD patients (2–83%→ 5.4–31.3%). The remaining variability was partly explained by primary substance of abuse and by country (Nordic versus non-Nordic countries). Prevalence estimates for DSM-5 were slightly higher than for DSM-IV. Given the generally high prevalence of adult ADHD, all treatment seeking SUD patients should be screened and, after a confirmed diagnosis, treated for ADHD since the literature indicates poor prognoses of SUD in treatment seeking SUD patients with ADHD.
登录
查看更多内容
影响因子：
4.4
作者：
Arias, Albert J.;Gelernter, Joel;Kranzler, Henry R.
通讯作者：
Kranzler, Henry R.
影响因子：
4.4
作者：
Friborg, Oddgeir;Bjorvatn, Bjorn;Pallesen, Stale
通讯作者：
Pallesen, Stale
影响因子：
7.3
作者：
CARROLL, KM;ROUNSAVILLE, BJ
通讯作者：
ROUNSAVILLE, BJ
影响因子：
10.6
作者：
Arns, Martijn;van der Heijden, Kristiaan B.;Kenemans, J. Leon
通讯作者：
Kenemans, J. Leon
影响因子：
--
作者：
Kessler, RC;Berglund, P;Walters, EE
通讯作者：
Walters, EE